Geneva, Oct. 8 -- International Clinical Trials Registry received information related to the study (ISRCTN10232579) titled 'A trial to investigate if psilocybin therapy is effective in improving outcomes for people with opioid use disorder' on Sept. 24.
Study Type: Interventional
Study Design:
Double-blind randomized controlled parallel-group trial (Other)
Primary Sponsor: Imperial College London
Condition:
Opioid use disorder
Mental and Behavioural Disorders
Intervention:
This is a two-arm, single-dose, double-blind, randomised, controlled, Phase IIa trial investigating psilocybin therapy in participants with opioid use disorder (OUD) in early abstinence. Participants will be randomised to receive either psilocybin (intervention...